It has been reported that the efficacy of a vaccine based on alphavirus replicon particles (VRP) expressing a melanoma antigen, relies on its ability to elicit specific antibodies that synergistically co-operate to tumor protection together with CD8+ T cells with a mechanism involving CD16 [44]. This evidence concerns the gene CD8A and melanoma.